Emmaus Life Sciences's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 111.69.
Emmaus Life Sciences's Days Inventory for the
three
months ended in Mar. 2026 was 940.74.
Emmaus Life Sciences's Days Payable for the
three
months ended in Mar. 2026 was 2673.41.
Therefore, Emmaus Life Sciences's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was -1,620.98.
Emmaus Life Sciences (OTCPK:EMMA) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Emmaus Life Sciences Cash Conversion Cycle Related Terms
Emmaus Life Sciences Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs CERO, AGTX, WINT: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Cash Conversion Cycle falls into.
Emmaus Life Sciences Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Emmaus Life Sciences's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -1,620.98 mean?
Emmaus Life Sciences (EMMA) has a Cash Conversion Cycle of -1,620.98 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Cash Conversion Cycle too high?
Emmaus Life Sciences' current Cash Conversion Cycle is -1,620.98.
How does Emmaus Life Sciences' Cash Conversion Cycle compare to CERO and AGTX?
Emmaus Life Sciences' Cash Conversion Cycle of -1,620.98 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.42, based on 874 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Cash Conversion Cycle is -1,620.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Cash Conversion Cycle is -1,620.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Cash Conversion Cycle is -1,620.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 